This firm's average rating is Sell from 5 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Clovis Oncology market sentiment investors' perception of the future value of Clovis. Let us look at a few aspects of Clovis technical analysis. About
61.0% of the company shares are held by institutions such as insurance companies. Clovis Oncology recorded a loss per share of
4.38. The entity had not issued any dividends in recent years.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of Clovis Oncology. In general, sophisticated investors focus on analyzing Clovis Oncology stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Clovis Oncology's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of
Clovis Oncology's intrinsic value. In addition to deriving basic predictive indicators for Clovis Oncology, many experienced traders also check how macroeconomic factors affect Clovis Oncology price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed
many market ups and downs, anticipate that the market will even out over time. This tendency of Clovis Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Clovis Oncology. Your research has to be compared to or analyzed against Clovis Oncology's peers to derive any actionable benefits. When done correctly, Clovis Oncology's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Clovis Oncology.
Watch out for price decline
Please consider monitoring Clovis Oncology on a daily basis if you are holding a position in it. Clovis Oncology is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Clovis Oncology stock to be traded above the $1 level to remain listed. If Clovis Oncology stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How does Clovis Stands against Peers?
Analyzing Clovis Oncology competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Clovis Oncology across multiple sectors and
thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out
Clovis Oncology Competition DetailsCloser look at Clovis Oncology Semi Deviation
Clovis Oncology has current Semi Deviation of 4.7. Semi-deviation provides a good measure of downside risk for a equity or a portfolio. It is similar to standard deviation, but it only looks at periods where the returns are less than the target or average level.
Semi-deviation is the square root of semi-variance. Semi-variance is calculated by averaging the deviations of returns that have a result that is less than the mean.
Semi Deviation | = | SQRT(SV) |
| = | 4.7 |
Let's now compare Clovis Oncology Semi Deviation to its closest peers:
| CLVS | 4.69679632896882 |
| DRNA | 3.18 |
| NK | 6.41 |
| DTIL | 4.45 |
| EQ | 4.58 |
Our take on today Clovis Oncology spike
Kurtosis is down to 0.35. It may connote a possible volatility fall. Clovis Oncology is displaying above-average volatility over the selected time horizon. Investors should scrutinize Clovis Oncology independently to ensure intended market timing strategies are aligned with expectations about Clovis Oncology volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Clovis Oncology's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Clovis Oncology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Final Perspective on Clovis Oncology
While some firms under the biotechnology industry are still a bit expensive, Clovis Oncology may offer a potential longer-term growth to retail investors. To conclude, as of the 19th of March 2021, we believe that at this point, Clovis Oncology is unstable with
high probability of distress within the next 2 years. From a slightly different point of view, the entity appears to be
undervalued. However, our primary 30 days 'Buy-vs-Sell' recommendation on the enterprise is
Strong Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Clovis Oncology. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com